PharmGKB ID,Literature,Variant,Drug,Class,phenotype,activity_score,Association,isomeric
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.4.001,(R)-methadone,nor,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
1451153742,PMID:11270921,CYP2D6.4.001; CYP2D6.4.001,(R)-methadone,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
1451153742,PMID:11270921,CYP2D6.4.001; CYP2D6.4.001,(S)-methadone,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.4.001,(S)-methadone,nor,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
1448109032,PMCID:PMC4949007,CYP2D6.4.001; CYP2D6.41.001,"3,4-methylenedioxymethamphetamine",de,CYP2D6 Intermediate Metabolizer,0.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC
1448109032,PMCID:PMC4949007,CYP2D6.4.001; CYP2D6.10.001,"3,4-methylenedioxymethamphetamine",de,CYP2D6 Intermediate Metabolizer,0.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC
1448109032,PMCID:PMC4949007,CYP2D6.3.001; CYP2D6.5.001,"3,4-methylenedioxymethamphetamine",f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*5 is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.6.001,"3,4-methylenedioxymethamphetamine",nor,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.10.001,"3,4-methylenedioxymethamphetamine",nor,CYP2D6 Normal Metabolizer,1.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC
1183617442,PMID:15590749,CYP2D6.4.001; CYP2D6.41.001,amitriptyline,de,CYP2D6 Intermediate Metabolizer,0.25,"CYP2D6 *4/*41 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1183617442,PMID:15590749,CYP2D6.1.001; CYP2D6.41.001,amitriptyline,nor,CYP2D6 Normal Metabolizer,1.25,"CYP2D6 *1/*4 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1183617442,PMID:15590749,CYP2D6.4.001; CYP2D6.10.001,amitriptyline,de,CYP2D6 Intermediate Metabolizer,0.25,"CYP2D6 *4/*10 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1183688948,PMID:20691935,CYP2D6.5.001; CYP2D6.41.001,atomoxetine,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *5/*41 are associated with increased risk of Drug Toxicity when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
1183688957,PMID:20691935,CYP2D6.1.001; CYP2D6.4.001,atomoxetine,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *1/*4 is associated with dose reduction to increase tolerability when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
1446896699,PMID:25919121,CYP2D6.3.001; CYP2D6.5.001,atomoxetine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
1446896699,PMID:25919121,CYP2D6.4.001; CYP2D6.4.001,atomoxetine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
1183688957,PMID:20691935,CYP2D6.2.001; CYP2D6.10.001,atomoxetine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *2/*10 is associated with dose reduction to increase tolerability when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
1447814438,PMID:26254792,CYP2D6.1.001; CYP2D6.10.001,atomoxetine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *1/*10 are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
982045318,PMID:20643254,CYP2D6.4.001; CYP2D6.5.001,carvedilol,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*5 is associated with increased dose of carvedilol in people with Heart Failure.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
827807099,PMID:21599570,CYP2D6.3.001; CYP2D6.3.001,carvedilol,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*3 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
982045318,PMID:20643254,CYP2D6.4.001; CYP2D6.6.001,carvedilol,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*6 is associated with increased dose of carvedilol in people with Heart Failure.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
827807126,PMID:21599570,CYP2D6.1.001; CYP2D6.1.001,carvedilol,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *6/*6 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
1183616659,PMID:15252821,CYP2D6.1.001; CYP2D6.4.001,clomipramine,de,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *1/*4 is associated with increased risk of side effects when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2.",CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
1446901449,PMID:16871470,CYP2D6.4.001; CYP2D6.6.001,clomipramine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*6 is associated with increased concentrations of clomipramine in people with Depressive Disorder, Major.",CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
1183701546,PMID:23981149,CYP2D6.10.001; CYP2D6.10.001,citalopram,de,CYP2D6 Intermediate Metabolizer,0.5,CYP2D6 *10/*10 is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
1452151321,PMID:18346175,CYP2D6.4.001; CYP2D6.4.001,clozapine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
1451152760,PMID:9352573,CYP2D6.3.001; CYP2D6.3.001,codeine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
1184756952,PMID:11823760,CYP2D6.1.001; CYP2D6.2.001,codeine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
1183632376,PMID:21743374,CYP2D6.4.001; CYP2D6.4.001,codeine,de,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 is associated with decreased analgesia from codeine for postpartum pain management when treated with codeine in women as compared to CYP2D6 *1/*1.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
1183632349,PMID:24077935,CYP2D6.10.001; CYP2D6.10.001,codeine,de,CYP2D6 Intermediate Metabolizer,0.5,"CYP2D6 *10/*10 is associated with decreased plasma levels of morphine, M3G and M6G levels but not those of codeine when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
1184756346,PMID:10471060,CYP2D6.18.001; CYP2D6.21.001,debrisoquine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *18/*21 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals.,C1CN(CC2=CC=CC=C21)C(=N)N
1184755514,PMID:8101460,CYP2D6.1.001; CYP2D6.9.001,debrisoquine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *1/*9 (assigned as normal metabolizers phenotype) is not associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.,C1CN(CC2=CC=CC=C21)C(=N)N
1184756875,PMID:11470994,CYP2D6.17.001; CYP2D6.29.001,debrisoquine,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *17/*29 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*17.,C1CN(CC2=CC=CC=C21)C(=N)N
1447990710,PMID:10022755,CYP2D6.4.001; CYP2D6.6.001,debrisoquine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*6 are associated with decreased metabolism of debrisoquine in healthy individuals.,C1CN(CC2=CC=CC=C21)C(=N)N
1184755565,PMID:8101460,CYP2D6.5.001; CYP2D6.9.001,debrisoquine,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *5/*9 (assigned as normal metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.,C1CN(CC2=CC=CC=C21)C(=N)N
1183622026,PMID:15115913,CYP2D6.1.001; CYP2D6.2.001,desipramine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *1/*4 is associated with increased desipramine elimination half-life and total exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1183621995,PMID:15115913,CYP2D6.6.001; CYP2D6.9.001,desipramine,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *6/*9 is associated with increased elimination half-life and drug exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1183622026,PMID:15115913,CYP2D6.1.001; CYP2D6.41.001,desipramine,de,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *1/*41 is associated with increased desipramine elimination half-life and total exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1451664485,PMID:32365274,CYP2D6.4.001; CYP2D6.4.001,desvenlafaxine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 is associated with decreased concentrations of desvenlafaxine in women with Depressive Disorder.,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
1184756714,PMID:20473659,CYP2D6.4.001; CYP2D6.31.001,dextromethorphan,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*31 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1184756472,PMID:15618746,CYP2D6.2.001; CYP2D6.44.001,dextromethorphan,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *2/*44 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*2.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1448604972,PMID:28290770,CYP2D6.12.001; CYP2D6.84.001,dextromethorphan,de,CYP2D6 Indeterminate,,CYP2D6 *12/*84 is associated with decreased metabolism of dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1446897151,PMID:16415111,CYP2D6.2.001; CYP2D6.36.001,dextromethorphan,nor,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *2/*36 (assigned as normal metabolizer phenotype) is not associated with decreased metabolism of dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1184989087,PMID:23394389,CYP2D6.2.001; CYP2D6.101.001,dextromethorphan,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *2/*101 is associated with decreased metabolism of dextromethorphan in healthy individuals.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1184757079,PMID:12152006,CYP2D6.4.001; CYP2D6.40.001,dextromethorphan,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*40 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1184756913,PMID:11823760,CYP2D6.5.001; CYP2D6.17.001,dextromethorphan,de,CYP2D6 Intermediate Metabolizer,0.5,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1184809445,PMID:16679388,CYP2D6.4.001; CYP2D6.56.001,dextromethorphan,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*56 (assigned as poor metabolizers phenotype) is associated with decreased enzyme activity of CYP2D6 when assayed with dextromethorphan in liver cells as compared to CYP2D6 *1/*1.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1184756902,PMID:11823760,CYP2D6.1.001; CYP2D6.2.001,dextromethorphan,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.",CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1183629560,PMCID:PMC2751283,CYP2D6.4.001; CYP2D6.6.001,dextromethorphan,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*6 is associated with decreased metabolism of debrisoquine or dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1184756523,PMID:15618746,CYP2D6.1.001; CYP2D6.21.001,dextromethorphan,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *1/*21 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*2.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
1451152920,PMCID:PMC2042888,CYP2D6.1.001; CYP2D6.1.001,dihydrocodeine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *4/*4 is associated with decreased metabolism of dihydrocodeine as compared to CYP2D6 *1/*1 + *1/*4.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O
1184511101,PMCID:PMC4168388,CYP2D6.4.001; CYP2D6.4.001,donepezil,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased likelihood of adverse events when treated with donepezil in people with Alzheimer Disease.,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
1183617426,PMCID:PMC2291379,CYP2D6.1.001; CYP2D6.1.001,doxepin,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31
1183617426,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,doxepin,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31
1451664500,PMID:32365274,CYP2D6.1.001; CYP2D6.1.001,duloxetine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *4/*4 is associated with increased concentrations of duloxetine in women with Depressive Disorder.,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
1183619829,PMID:21926427,CYP2D6.4.001; CYP2D6.41.001,escitalopram,de,CYP2D6 Intermediate Metabolizer,0.25,"CYP2D6 *4/*41 is associated with increased mean logarithm escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
1451152700,PMCID:PMC1364985,CYP2D6.1.001; CYP2D6.1.001,ethylmorphine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *4/*4 is associated with decreased enzyme activity of CYP2D6 when assayed with ethylmorphine as compared to CYP2D6 *1/*1 + *1/*4.,CCOC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CCN4C)[C@@H](O2)[C@H](C=C5)O)C=C1
1451208192,PMID:25825958,CYP2D6.1.001; CYP2D6.1.001,fentanyl,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *10/*10 is associated with increased dose of fentanyl in people with Gastrointestinal Neoplasms and Pain, Postoperative as compared to CYP2D6 *1/*1.",CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
1183621673,PMID:16944116,CYP2D6.10.001; CYP2D6.36.001,flecainide,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *10/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F
1183617434,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,fluvoxamine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.",COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F
1184137435,PMID:18978520,CYP2D6.1.001; CYP2D6.10.001,fluvoxamine,de,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *1/*10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F
1184137435,PMID:18978520,CYP2D6.1.001; CYP2D6.5.001,fluvoxamine,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *1/*5 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F
1184135927,PMID:23503455,CYP2D6.1.001; CYP2D6.1.001,galantamine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
1184135944,PMID:23503455,CYP2D6.5.001; CYP2D6.41.001,galantamine,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *5/*41 (assigned as heterozygous normal metabolizer phenotype) are not associated with dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
1184135927,PMID:23503455,CYP2D6.4.001; CYP2D6.5.001,galantamine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
1447948592,PMID:16719544,CYP2D6.1.001; CYP2D6.3.001,gefitinib,nor,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
1447948592,PMID:16719544,CYP2D6.3.001; CYP2D6.5.001,gefitinib,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*5(assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
1447948592,PMID:16719544,CYP2D6.4.001; CYP2D6.4.001,gefitinib,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
1447948127,PMID:26323212,CYP2D6.1.001; CYP2D6.1.001,gefitinib,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *10/*10 (assigned as poor metabolizer phenotype) is associated with increased risk of Toxic liver disease when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*14 + *2/*5 + *2/*10.",COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
1447948127,PMID:26323212,CYP2D6.10.001; CYP2D6.10.001,gefitinib,de,CYP2D6 Intermediate Metabolizer,0.5,"CYP2D6 *10/*10 (assigned as poor metabolizer phenotype) is associated with increased risk of Toxic liver disease when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*14 + *2/*5 + *2/*10.",COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.5.001,haloperidol,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1452151189,PMID:18346175,CYP2D6.3.001; CYP2D6.4.001,haloperidol,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1452151321,PMID:18346175,CYP2D6.1.001; CYP2D6.1.001,haloperidol,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1451152760,PMID:9352573,CYP2D6.1.001; CYP2D6.3.001,hydrocodone,nor,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
1451141860,PMCID:PMC6960206,CYP2D6.5.001; CYP2D6.17.001,hydrocodone,de,CYP2D6 Intermediate Metabolizer,0.5,CYP2D6 *5/*17 is associated with decreased response to hydrocodone or tramadol in women.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
1451152760,PMID:9352573,CYP2D6.3.001; CYP2D6.3.001,hydrocodone,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
1446900845,PMID:9014200,CYP2D6.3.001; CYP2D6.4.001,imipramine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*5 + *1/*3 + *1/*4.,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1183617426,PMCID:PMC2291379,CYP2D6.1.001; CYP2D6.1.001,maprotiline,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
1450822217,PMID:30815856,CYP2D6.1.001; CYP2D6.2.001,mephedrone,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *1/*9 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC
1450822217,PMID:30815856,CYP2D6.1.001; CYP2D6.4.001,mephedrone,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *1/*4 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC
1450971020,PMID:29843110,CYP2D6.2.001; CYP2D6.4.001,methamphetamine,nor,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC
1450971020,PMID:29843110,CYP2D6.1.001; CYP2D6.10.001,methamphetamine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC
1450971020,PMID:29843110,CYP2D6.4.001; CYP2D6.10.001,methamphetamine,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC
1452196960,PMID:33247397,CYP2D6.1.001; CYP2D6.10.001,metoclopramide,de,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *1/*10 is associated with decreased clearance of metoclopramide in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
1184756685,PMID:15726636,CYP2D6.4.001; CYP2D6.31.001,metoprolol,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*31 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of metoprolol in healthy individuals.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
1184756902,PMID:11823760,CYP2D6.17.001; CYP2D6.17.001,metoprolol,de,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.",CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
1184085740,PMCID:PMC4111800,CYP2D6.4.001; CYP2D6.41.001,metoprolol,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *4/*41 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
1184756902,PMID:11823760,CYP2D6.1.001; CYP2D6.2.001,metoprolol,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.",CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
1444703011,PMID:9408809,CYP2D6.5.001; CYP2D6.10.001,mianserin,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *5/*10 are associated with increased concentrations of mianserin in people with Depression as compared to CYP2D6 *1/*1.,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
1183618754,PMID:22926595,CYP2D6.4.001; CYP2D6.6.001,mirtazapine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*6 are associated with increased S-mirtazapine plasma levels in non-smokers at day 14 of treatment when treated with mirtazapine in people with Depression as compared to CYP2D6 *1/*1.,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
1446902725,PMID:15590749,CYP2D6.4.001; CYP2D6.10.001,nortriptyline,de,CYP2D6 Intermediate Metabolizer,0.25,"CYP2D6 *4/*10 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1446902725,PMID:15590749,CYP2D6.2.001; CYP2D6.2.001,nortriptyline,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *2/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1183617426,PMCID:PMC2291379,CYP2D6.1.001; CYP2D6.1.001,nortriptyline,nor,CYP2D6 Normal Metabolizer,2,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1452151189,PMID:18346175,CYP2D6.3.001; CYP2D6.4.001,olanzapine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1183617426,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,opipramol,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO
1184473395,PMCID:PMC3610662,CYP2D6.4.001; CYP2D6.6.001,oxycodone,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*6(assigned as poor metabolizer phenotype) is associated with decreased Mean oxymophone/oxycodone ratios when treated with oxycodone as compared to CYP2D6 *1/*1xN + *2/*2xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype) .,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
1451152760,PMID:9352573,CYP2D6.1.001; CYP2D6.4.001,oxycodone,de,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
1451643140,PMID:34231053,CYP2D6.1.001; CYP2D6.9.001,paroxetine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
1183620663,PMID:19743889,CYP2D6.3.001; CYP2D6.4.001,paroxetine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*4 is associated with increased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
1444712725,PMID:25967538,CYP2D6.10.001; CYP2D6.41.001,paroxetine,de,CYP2D6 Intermediate Metabolizer,0.5,CYP2D6 *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
1451643140,PMID:34231053,CYP2D6.2.001; CYP2D6.41.001,paroxetine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
1451643140,PMID:34231053,CYP2D6.5.001; CYP2D6.9.001,paroxetine,f,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *5/*9 (assigned as intermediate metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
1183621064,PMID:18641553,CYP2D6.1.001; CYP2D6.6.001,paroxetine,de,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *1/*6 is associated with nonsignificantly higher paroxetine concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
1447954876,PMCID:PMC4757974,CYP2D6.10.001; CYP2D6.41.001,primaquine,de,CYP2D6 Intermediate Metabolizer,0.5,CYP2D6 *10/*41 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
1447954876,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.2.001,primaquine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *1/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
1447954876,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.41.001,primaquine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *1/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
1183681888,PMID:17986163,CYP2D6.4.001; CYP2D6.4.001,promethazine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 is associated with akathisia when treated with promethazine in women.,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
1451294540,PMID:33203295,CYP2D6.1.001; CYP2D6.2.001,propafenone,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *1/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
1451294540,PMID:33203295,CYP2D6.5.001; CYP2D6.10.001,propafenone,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
1452151321,PMID:18346175,CYP2D6.4.001; CYP2D6.4.001,quetiapine,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
1183702193,PMID:24329187,CYP2D6.4.001; CYP2D6.4.001,risperidone,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
1448530382,PMID:26944100,CYP2D6.1.001; CYP2D6.41.001,risperidone,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
1448530382,PMID:26944100,CYP2D6.1.001; CYP2D6.5.001,risperidone,nor,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
1448530486,PMID:26944100,CYP2D6.4.001; CYP2D6.10.001,risperidone,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *4/*10 are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
1184757252,PMID:17460029,CYP2D6.41.001; CYP2D6.62.001,sparteine,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *41/*62 is associated with decreased metabolism of sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4
1447990337,PMID:2211621,CYP2D6.3.001; CYP2D6.4.001,sparteine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*4 are associated with decreased metabolism of debrisoquine or sparteine.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4
1184986233,PMID:9511177,CYP2D6.2.001; CYP2D6.2.001,sparteine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4
1447954841,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.41.001,tafenoquine,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
1447954841,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.4.001,tafenoquine,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *2/*4 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
1447954841,PMCID:PMC4757974,CYP2D6.4.001; CYP2D6.41.001,tafenoquine,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
1448260990,PMCID:PMC4522133,CYP2D6.2.001; CYP2D6.6.001,tamoxifen,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *2/*6 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444713029,PMID:20515869,CYP2D6.6.001; CYP2D6.7.001,tamoxifen,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *6/*7 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444708449,PMID:18024866,CYP2D6.10.001; CYP2D6.41.001,tamoxifen,de,CYP2D6 Intermediate Metabolizer,0.5,CYP2D6 *10/*41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444712127,PMID:16815318,CYP2D6.3.001; CYP2D6.41.001,tamoxifen,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *41/*3 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444934955,PMCID:PMC3726442,CYP2D6.5.001; CYP2D6.17.001,tamoxifen,f,CYP2D6 Intermediate Metabolizer,0.5,CYP2D6 *5/*17 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9 + *1/*17 + *1/*41.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1448261067,PMID:26847054,CYP2D6.1.001; CYP2D6.10.001,tamoxifen,nor,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *3/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*2xN + *1/*10 + *9/*41 + *2/*10 + *2/*2 + *1/*1xN + *1/*41 + *1/*9 + *1/*5 + *1/*4 + *10/*10 + *2/*4 + *2/*5 + *2/*41 + *2/*9.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444711981,PMID:16815318,CYP2D6.5.001; CYP2D6.9.001,tamoxifen,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *9/*5 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1448261067,PMID:26847054,CYP2D6.3.001; CYP2D6.4.001,tamoxifen,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*2xN + *1/*10 + *9/*41 + *2/*10 + *2/*2 + *1/*1xN + *1/*41 + *1/*9 + *1/*5 + *1/*4 + *10/*10 + *2/*4 + *2/*5 + *2/*41 + *2/*9.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444713029,PMID:20515869,CYP2D6.3.001; CYP2D6.6.001,tamoxifen,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*6 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444711981,PMID:16815318,CYP2D6.1.001; CYP2D6.35.001,tamoxifen,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *2/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1444709657,PMID:22623212,CYP2D6.1.001; CYP2D6.1.001,tamoxifen,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *4/*4 are associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*4.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
1183690112,PMID:16315032,CYP2D6.3.001; CYP2D6.4.001,timolol,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*4 is associated with increased exposure to timolol (higher area-under-curve, longer elimination half-lives ) when exposed to timolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
1451552540,PMID:32538291,CYP2D6.1.001; CYP2D6.9.001,tramadol,de,CYP2D6 Normal Metabolizer,1.25,CYP2D6 *1/*9 (assigned as intermediate metabolizer genotype phenotype) are associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer genotype phenotype) .,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1451208260,PMID:25989235,CYP2D6.6.001; CYP2D6.10.001,tramadol,de,CYP2D6 Intermediate Metabolizer,0.25,"CYP2D6 *6/*10 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1183618098,PMID:14499440,CYP2D6.6.001; CYP2D6.6.001,tramadol,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *6/*6 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1451565700,PMID:33131142,CYP2D6.1.001; CYP2D6.5.001,tramadol,de,CYP2D6 Intermediate Metabolizer,1,CYP2D6 *1/*5 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1183618044,PMID:17361124,CYP2D6.3.001; CYP2D6.5.001,tramadol,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*5 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1451208260,PMID:25989235,CYP2D6.1.001; CYP2D6.41.001,tramadol,nor,CYP2D6 Normal Metabolizer,1.25,"CYP2D6 *1/*3 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1451157780,PMID:18317231,CYP2D6.4.001; CYP2D6.5.001,tramadol,de,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*5 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1451565700,PMID:33131142,CYP2D6.1.001; CYP2D6.2.001,tramadol,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *1/*5 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
1446901857,PMID:14646691,CYP2D6.3.001; CYP2D6.3.001,trimipramine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *3/*3 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN.,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
1447148428,PMID:12728290,CYP2D6.5.001; CYP2D6.10.001,tropisetron,de,CYP2D6 Intermediate Metabolizer,0.25,CYP2D6 *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
982029525,PMID:18214456,CYP2D6.1.001; CYP2D6.3.001,venlafaxine,de,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
1452022006,PMID:31794166,CYP2D6.41.001; CYP2D6.41.001,venlafaxine,de,CYP2D6 Intermediate Metabolizer,0.5,CYP2D6 *41/*41 is associated with increased likelihood of Serotonin Syndrome when treated with venlafaxine in people with Depression.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
1450815182,PMID:23332809,CYP2D6.4.001; CYP2D6.5.001,venlafaxine,f,CYP2D6 Poor Metabolizer,0,CYP2D6 *4/*5 is associated with decreased metabolism of venlafaxine.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
1450934262,PMID:31799914,CYP2D6.1.001; CYP2D6.4.001,venlafaxine,de,CYP2D6 Intermediate Metabolizer,1,"CYP2D6 *1/*4 is associated with increased cardiotoxicity, Edema, Nausea and Vomiting when treated with venlafaxine in men with Alcohol-Related Disorders.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
1451888600,PMID:35703273,CYP2D6.1.001; CYP2D6.1.001,vortioxetine,nor,CYP2D6 Normal Metabolizer,2,CYP2D6 *4/*4 is associated with increased concentrations of vortioxetine as compared to CYP2D6 *1/*1.,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
1452151321,PMID:18346175,CYP2D6.4.001; CYP2D6.4.001,zuclopenthixol,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
1452151189,PMID:18346175,CYP2D6.3.001; CYP2D6.4.001,zuclopenthixol,f,CYP2D6 Poor Metabolizer,0,"CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
